BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,735,933 | +53.3% | 331,283 | 0.0% | 0.68% | +17.8% |
Q2 2023 | $5,698,068 | +3.7% | 331,283 | 0.0% | 0.57% | +12.1% |
Q1 2023 | $5,492,672 | +117.6% | 331,283 | 0.0% | 0.51% | +99.6% |
Q4 2022 | $2,524,376 | -23.3% | 331,283 | 0.0% | 0.26% | +21.9% |
Q3 2022 | $3,293,000 | +9.5% | 331,283 | 0.0% | 0.21% | +3.4% |
Q2 2022 | $3,008,000 | -10.6% | 331,283 | 0.0% | 0.20% | +6.8% |
Q1 2022 | $3,363,000 | -39.1% | 331,283 | 0.0% | 0.19% | -45.2% |
Q4 2021 | $5,526,000 | -64.4% | 331,283 | 0.0% | 0.35% | -70.0% |
Q3 2021 | $15,527,000 | -23.1% | 331,283 | 0.0% | 1.16% | -38.7% |
Q2 2021 | $20,195,000 | -1.0% | 331,283 | 0.0% | 1.89% | +4.5% |
Q1 2021 | $20,407,000 | – | 331,283 | – | 1.80% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |